Few questions in the FMT field generate more interest — or more confusion — than whether Fecal Microbiota Transplantation can help children with Autism Spectrum Disorder (ASD). Families reach out to our clinic regularly after reading headlines about microbiome research and autism. I want to walk through what the published evidence actually shows, what it doesn't show, and how I think about this clinically.
Why Researchers Are Studying the Gut in Autism
Up to 70% of children with ASD experience chronic gastrointestinal symptoms — constipation, diarrhea, abdominal pain, and reflux — at rates dramatically higher than the general pediatric population. Multiple studies have also documented measurable differences in gut microbiome composition between children with autism and neurotypical controls, including reduced microbial diversity, lower levels of beneficial species like Bifidobacterium and Prevotella, and altered short-chain fatty acid profiles.
These findings, combined with growing recognition of the gut-brain axis as a real, mechanistic communication system, have driven interest in whether modifying the microbiome could improve both GI symptoms and behavioral measures in ASD.
The Arizona State University Studies
The most cited research on FMT for autism comes from Dr. James Adams and colleagues at Arizona State University, who developed a modified protocol called Microbiota Transfer Therapy (MTT). Their 2017 open-label study, published in Microbiome, treated 18 children with ASD and chronic GI symptoms with a two-week vancomycin pretreatment followed by an extended course of FMT.
The results were striking: an 80% reduction in GI symptoms that persisted at the eight-week endpoint, along with significant improvements on standardized behavioral assessments including the Childhood Autism Rating Scale (CARS) and the Social Responsiveness Scale (SRS). A 2019 follow-up published in Scientific Reports reported that two years after treatment, GI improvements were maintained and ASD symptom severity had continued to decrease.
These outcomes generated significant excitement, and rightly so. But it's important to be honest about the limitations: the original study was open-label (not blinded, no placebo control), the sample size was small, and the modified protocol used in these trials differs substantially from standard FMT.
What the Evidence Doesn't Yet Establish
As of this writing, there is no large randomized, placebo-controlled trial of FMT for ASD that has been published and peer-reviewed. The pediatric clinical trials that would establish FMT as a proven treatment for autism are ongoing but not complete. The FDA has not approved FMT for autism, and any use for this indication is investigational.
We also don't yet know which children are most likely to respond, what the optimal protocol is, how long benefits last beyond two years, or whether the behavioral improvements documented in the open-label trials would hold up under blinded conditions. These are real, open scientific questions.
How I Think About This Clinically
This article discusses published research, not an offer of pediatric FMT or a claim that FMT treats autism. Research participation and clinical treatment have different requirements. Pediatric symptoms should be reviewed with the child's established pediatric and specialist care team.
A consultation or parental consent alone does not authorize investigational treatment. Appropriate regulatory authorization, including an investigational new drug application where required, must be established separately.
Questions to Ask Any Clinic
If you're researching FMT for a child with autism, I'd encourage you to ask any clinic the following: What specific protocol do you use, and how does it compare to the published research? How are donors screened? What outcomes do you measure, and how are families followed long-term? Are there any conflicts of interest that might affect the recommendations you receive?
These are reasonable questions for the child's established care team and any appropriately authorized research program. Donor-material FMT is investigational, and this research summary does not establish pediatric eligibility or promise benefit.
